CALGB 80403 (Alliance)/E1206: A randomized phase II study of three chemotherapy regimens plus cetuximab in metastatic esophageal and gastroesophageal Junction Cancers Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Antineoplastic Agents
  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Squamous Cell
  • Esophageal Neoplasms
  • Esophagogastric Junction

abstract

  • In combination with cetuximab, ECF and FOLFOX had similar efficacy, but FOLFOX was better tolerated. Although differences were nonsignificant, IC plus cetuximab seemed to be the least effective and most toxic of the three regimens tested.

publication date

  • August 10, 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5019745

Digital Object Identifier (DOI)

  • 10.1200/JCO.2015.65.5092

PubMed ID

  • 27382098

Additional Document Info

start page

  • 2736

end page

  • 42

volume

  • 34

number

  • 23